Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    82
    ...
ATC Name B/G Ingredients Dosage Form Price
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 159,736 L.L
C10AA05 TARDELIP G Atorvastatin - 20mg 20mg Tablet, film coated 880,537 L.L
G04BE03 VIRECTA G Sildenafil - 100mg 100mg Tablet, film coated 584,571 L.L
J01CR02 AMOCLAN BID G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet 456,906 L.L
J01MA02 CIPROCIN G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 240,548 L.L
J07AH08 MENQUADFI G Meningococcal (serogroups A, C, W and Y) conjugate vaccine - Injectable solution 4,859,334 L.L
N03AX16 PMS-PREGABALIN G Pregabalin - 75mg 75mg Capsule 1,776,560 L.L
N06AB05 PMS-PAROXETINE G Paroxetine (HCl) - 20mg 20mg Tablet 731,050 L.L
L01CD04 CABAZITAXEL EVER PHARMA G Cabazitaxel - 60mg/6ml 10mg/ml Injectable concentrate for solution L.L
A02BC01 OMEPRAL G Omeprazole - 20mg 20mg Capsule, delayed release 213,735 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 179,272 L.L
C03CA01 APO-FUROSEMIDE G Furosemide - 40mg 40mg Tablet, scored 862,747 L.L
C09CA01 LOSANET G Losartan potassium - 100mg 100mg Tablet 395,474 L.L
C10AA05 TARDEN G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 880,537 L.L
G04BE03 SILDENAFIL STRAGEN G Sildenafil - 20mg 20mg Tablet, coated 38,048,630 L.L
J01CR02 ARDINECLAV G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet 431,309 L.L
J01MA02 CIPRODAR G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 392,402 L.L
M01AE01 PROFINAL G Ibuprofen - 600mg 600mg Tablet 302,365 L.L
N03AX16 PREGABADOR G Pregabalin - 75mg 75mg Capsule, hard 364,181 L.L
N06AB05 UNIROX G Paroxetine (HCl) - 20mg 20mg Tablet, film coated 854,684 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 1mg 1mg Tablet, coated L.L
A02BC01 OMEPRAZOLE PHARMADEX G Omeprazole - 20mg 20mg Capsule 415,951 L.L
A07EA02 HEMORRANE G Hydrocortisone acetate - 10mg/g 10mg/g Ointment 710,893 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 191,913 L.L
C03CA01 BIOLASOMIDE G Furosemide - 40mg 40mg Tablet 181,419 L.L
C09CA01 LOSARTAN BIOGARAN G Losartan potassium - 100mg 100mg Tablet, coated 439,436 L.L
C10AA05 TORVACOL 20 G Atorvastatin (calcium) - 20mg 20mg Tablet, coated 1,128,828 L.L
D07CC01 BETAFUCIN G Fusidic acid - 20mg/g, Betamethasone valerate - 1mg/1g Cream 210,983 L.L
J01CR02 CURAM G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet, film coated 520,619 L.L
J01MA02 CIPROFAR G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 241,892 L.L
    ...
    82
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025